Company news
C4 Therapeutics, Inc. news in 2022
C4 Therapeutics, Inc.'s news releases, calls and decks from 2022, newest first.
C4 Therapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights
November 2, 2022
C4 Therapeutics Receives Study May Proceed Letter from U.S. FDA to Initiate Phase 1/2 Clinical Trial of CFT1946, an Orally Bioavailable BiDAC™ Degrader, in BRAF-V600 Mutant Solid Cancers
September 28, 2022
C4 Therapeutics to Present at Bank of America Securities Precision Oncology Conference 2022
September 25, 2022
C4 Therapeutics Reports Second Quarter 2022 Financial Results and Recent Business Highlights
August 3, 2022
C4 Therapeutics Appoints Experienced Clinical Development Leaders Laura Bessen, M.D. and Donna Grogan, M.D. to Board of Directors
August 1, 2022
C4 Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating CFT8634, an Orally Bioavailable BiDAC™ Degrader for the Treatment of Synovial Sarcoma and SMARCB1-null Tumors
May 15, 2022
C4 Therapeutics Reports First Quarter 2022 Financial Results and Recent Business Highlights
May 4, 2022
C4 Therapeutics Presents Clinical Data from Cohort A of the Ongoing Phase 1/2 Clinical Trial of CFT7455, a Novel IKZF1/3 Degrader
April 7, 2022
C4 Therapeutics Appoints Utpal Koppikar to Board of Directors
March 15, 2022
C4 Therapeutics Announces FDA Orphan Drug Designation for CFT8634 for the Treatment of Soft Tissue Sarcoma
March 8, 2022
C4 Therapeutics to Present at the American Association for Cancer Research (AACR) Annual Meeting 2022
March 7, 2022
C4 Therapeutics Reports Full Year 2021 Financial Results and Recent Business Highlights
February 23, 2022
C4 Therapeutics Announces 2022 Key Milestones to Advance Targeted Protein Degradation Portfolio
January 9, 2022
C4 Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
January 2, 2022
Decks in 2022
- Technical Presentation (April 2022)
Technical · 25 slides · Apr 8, 2022